Nijmegen/Amsterdam, January 10, 2017
Okklo Life Sciences B.V. and Sanquin sign commercialization agreement to enter IND enabling studies and clinical development.
Okklo Life Sciences B.V. (Nijmegen, The Netherlands) and Sanquin Blood Supply Foundation (Amsterdam, the Netherlands) today announced that they have signed an agreement regarding the further development and commercialization of their first in class pro-haemostatic cyclodextrins.
The agreement covers the (pre-)clinical development and commercialization of several lead compounds in the field of haemostasis. These ring-shaped sugar molecules belong to the class of cyclodextrins, and represent the first non-peptidergic compounds that may be used as pro-coagulants.
Okklo and Sanquin have jointly developed a series of proprietary cyclodextrins that have shown strong pro-haemostatic effects in in vitro and in vivo models of both, anticoagulant reversal and haemophilia. Accordingly, these first in class molecules will now be further developed for the treatment or prevention of acute bleedings (including reversal of anticoagulant effects) and the treatment of bleeding disorders such as haemophilia.
The initial development plan includes the execution of IND-enabling studies and a phase I study. These studies may be performed by Okklo and Sanquin themselves, or in collaboration with a partner. The parties are now actively looking for co-development partners.
Okklo Life Sciences BV is a privately held company located in Nijmegen, The Netherlands, and is developing new therapeutics based on cyclodextrins as the active ingredient. Currently, Okklo’s own pre-clinical programs focus on two separate therapeutic areas with high unmet medical need: hemostasis and lysosomal storage diseases. www.okklo.com
Sanquin Blood Supply Foundation is responsible for safe and efficient blood supply in the Netherlands on a not-for-profit basis. This is possible because hundreds of thousands of donors voluntarily give blood. The core activity is safe and efficient production and distribution of blood and plasma products for the treatment of patients. Sanquin also develops and produces pharmaceutical products, conducts high-quality scientific research, and develops and performs a multitude of diagnostic services. Continuous research and innovation lead to new and improved products and services. www.sanquin.nl
For more information, please contact:
Alex Zwiers, Okklo Life Sciences
phone +31 6 1048 9150
Robert Heckert, Sanquin Blood Supply Foundation
phone +31 20 512 3998